Heart drug camzyos may do more than relieve blockage – new study investigates
NCT ID NCT07120776
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This study looks at whether the medication Camzyos (mavacamten) improves blood supply to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM). About 75 adults already prescribed Camzyos will get a special PET scan before starting the drug and again after 12 months. The goal is to see if Camzyos reduces chest pain and shortness of breath by easing a lack of oxygen in the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY \(HOCM\) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manchester University NHS Foundation Trust
RECRUITINGManchester, M13 9WL, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.